ERp57 is associated not only with myeloproliferative neoplasms, but also with many disease states of CNS, such as prion disorders and AD, where ERp57 and calreticulin have been shown to prevent amyloid aggregation (Coe and Michalak, 2010). Here, PDIA3 is linked to myeloproliferative disorder.